Matrix Metalloproteinases

  • Viola VargováEmail author
  • Marek Pytliak
  • Viola Mechírová
Part of the Experientia Supplementum book series (EXS, volume 103)


Remodeling of extracellular matrix is crucial for many physiological (cell migration, proliferation, growth, and development) and pathological (remodeling of heart, carcinogenesis, metastasis, etc.) events. Thus, the interaction between cells and extracellular matrix plays a key role in normal development and differentiation of organism and many pathological states as well. Changes in extracellular matrix are regulated by a system of proteolytic enzymes that are responsible for proteolysis of huge quantity of extracellular matrix components. Matrix metalloproteinases (MMPs) represent the main group of regulating proteases in ECM. Ability of matrix metalloproteinases to modify the structural integrity of tissues is essential for certain aspects of normal physiology and pathology. The ability to process molecules such as growth factors, receptors, adhesion molecules, other proteinases, and proteinase inhibitors makes MMPs potent controllers of physiological and pathological events in the cell microenvironment. Overactivation of MMPs has been implicated in numerous disease states.


Matrix metalloproteinases Cardiovascular risk Hypertension Diabetes Oncogenesis Pulmonary hypertension 



Angiotensin converting enzyme


A Disintegrin and Metalloproteinase




Angiotensin receptor blocker


Bronchoalveolar lavage fluid


Brain natriuretic peptide


Cyclic guanosine monophosphate


Chronic obstructive pulmonary disease


Deoxycorticosterone acetate


Extracellular matrix


Fibroblast growth factor


Fibroblast-like synoviocytes


Heart failure


Idiopathic pulmonary fibrosis






Inhibitors of matrix metalloproteinases


Matrix metalloproteinases


Pulmonary arterial hypertension


Platelet-derived growth factor


Prostaglandin E


Protein kinase G


Peroxisome proliferator-activated receptor gamma


Reversion-inducing-cysteine-rich protein with kazal motifs


Systemic lupus erythematosus


Systemic sclerosis


Transforming growth factor-beta


Tissue inhibitors of matrix metalloproteinases


Tumor necrosis factor alpha


Vascular smooth muscle cells


Wild type


Zinc-binding group


  1. Agrez M, Chen A, Cone RI, Pytela R, Sheppard D (1994) The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol 127:547–556PubMedGoogle Scholar
  2. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL (2002) Fibrosis, matrix metalloproteinases, and inflammation in heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension 36:679–684Google Scholar
  3. Atkinson JJ, Senior RM (2003) Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28:12–24PubMedGoogle Scholar
  4. Augustin S, Berard M, Kellaf S, Peyri N, Fauvel-Lefève F, Legrand C, He L, Crépin M (2009) Matrix metalloproteinases are involved in both type I (apoptosis) and type II (autophagy) cell death induced by sodium phenylacetate in MDA-MB-231 breast tumor cells. Anticancer Res 29:1335–1343PubMedGoogle Scholar
  5. Babčák M, Merčiaková M, Kmec J, Jenča J (2004) Diabetes mellitus 2. typ a artériová hypertenzia – najnovšie ponatky. Diabetes a obezita 4:15–41Google Scholar
  6. Baugh MD, Gavrilovic J, Davies IR, Hughes DA, Sampson MJ (2003) Monocyte matrix metalloproteinase production in Type 2 diabetes and control – a cross sectional study. Cardiovasc Diabetetol 2:3Google Scholar
  7. Becker JW, Marcy AI, Rokosz LL, Axel MG et al (1995) Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci 4:1966–1976PubMedGoogle Scholar
  8. Bendeck MP, Zempo N, Clowes AW et al (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75:539–545PubMedGoogle Scholar
  9. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A (2002) Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 90:784–791PubMedGoogle Scholar
  10. Betsuyaku T, Nishimura M, Takeyabu K et al (1999) Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 59(6):1985–1991Google Scholar
  11. Betsuyaku T, Tanino M, Nagai K et al (2003) Extracellular matrix metalloproteinase inducer is increased in smokers’ bronchoalveolar lavage fluid. Am J Respir Crit Care Med 168(2):222–227PubMedGoogle Scholar
  12. Bhattacharyya P, Acharya D, Roychowdhury S (2007) Role of matrix metalloproteinases in the pathophysiology of idiopathic pulmonary fibrosis. Lung India 24:61–65Google Scholar
  13. Borkakoti N (2000) Structural studies of matrix metalloproteinases. J Mol Med 78:261–268PubMedGoogle Scholar
  14. Borkakoti N, Winkler FK, Williams DH, D’Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ (1994) Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol 1:106–110PubMedGoogle Scholar
  15. Boudreau N, Sympson CJ, Werb Z, Bissell MJ (1995) Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891–893PubMedGoogle Scholar
  16. Cameron VA, Rademaker MT, Ellmers LJ, Espiner EA, Nicholls MG, Richards AM (2000) Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology 141:4690–4697PubMedGoogle Scholar
  17. Cataldo DD, Gueders MM, Rocks N, Sounni NE et al (2003) Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol 49(6):875–884PubMedGoogle Scholar
  18. Cedro K, Radomski A, Radomski MW, Ruźy W, Herbaczyska-Cedro K (2003) Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study. Int J Cardiol 92(2–3):177–180PubMedGoogle Scholar
  19. Chang Y-H, Lin I-L, Tsay G-J, Yang S-C, Yang T-P, Ho K-T, Hsu T-C, Shiau M-Y (2008) Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 41:955–959PubMedGoogle Scholar
  20. Chen LC, Noelken ME, Nagase H (1993) Disruption of the cysteine 75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin-1). Biochemistry 32:10289–10295PubMedGoogle Scholar
  21. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP (2001) Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89:201–210PubMedGoogle Scholar
  22. Death AK, Fisher EJ, McGrath KCY, Yue DK (2003) High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168:263–269PubMedGoogle Scholar
  23. Derosa G, Avanzini MA, Geroldi D, Fogari R et al (2004) Matrix metalloproteinase 2 may be a marker of macroangiopathy in children and adolescents with type 1 diabetes. Diabetes Care 27:273–274PubMedGoogle Scholar
  24. Derosa G, D’Angelo A, Ciccarelli L, Piccinni MN et al (2006) Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13:227–231PubMedGoogle Scholar
  25. Dollery CM, McEwan J, Henney A (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863–868PubMedGoogle Scholar
  26. Ducharme A, Frantz S, Aikawa M, Rabkin E et al (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55–62PubMedGoogle Scholar
  27. Duhamel-Clerin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C (1997) Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol 17:1931–1938PubMedGoogle Scholar
  28. Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29(5):258–289PubMedGoogle Scholar
  29. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174PubMedGoogle Scholar
  30. Elshaw SR, Henderson N, Knox AJ, Watson SA, Buttle DJ, Johnson SR (2004) Matrix metalloproteinase expression and activity in human airway smooth muscle cells. Br J Pharmacol 42(8):1318–1324Google Scholar
  31. Felkin LE, Lara-Pezzi E, George R, Yacoub MH, Birks EJ, Barton PJ (2009) Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant 28(2):117–122PubMedGoogle Scholar
  32. Fernandez-Catalan C, Bode W, Huber R, Turk D et al (1998) Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 17(17):5238–5248PubMedGoogle Scholar
  33. Fingleton B (2003) Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 7(3):385–397PubMedGoogle Scholar
  34. Finlay GA, Russell KJ, McMahon KJ et al (1997) Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 52(6):502–506PubMedGoogle Scholar
  35. Flamant M, Placier S, Dubroca C, Esposito B et al (2007) Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50:212–218PubMedGoogle Scholar
  36. Fridman R (2006) Metalloproteinases and cancer. Cancer Metastasis Rev 25:7–8Google Scholar
  37. Fridman R, Fuerst TR, Bird RE, Hoyhtya M et al (1992) Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem 267:15398–15405PubMedGoogle Scholar
  38. Frisdal E, Gest V, Vieillard-Baron A, Levame M et al (2001) Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 18:838–845PubMedGoogle Scholar
  39. Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res 90:251–262PubMedGoogle Scholar
  40. Galis Z, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P (1995) Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 748:501–507PubMedGoogle Scholar
  41. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E (2002) Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91:852–859PubMedGoogle Scholar
  42. Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C (2007) Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 35(4):689–691PubMedGoogle Scholar
  43. Ge J, Shen Ch, Liang Ch, Chen L, Qian J, Chen H (2006) Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. Int J Cardiol 112:85–90PubMedGoogle Scholar
  44. Gross J, Lapiere C (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 48:1014–1022PubMedGoogle Scholar
  45. Gueders MM, Foidart J-M, Noel A, Cataldo DD (2006) Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 533:133–144PubMedGoogle Scholar
  46. Han Z, Junxu, Zhong N (2003) Expression of matrix metalloproteinases MMP-9 within the airways in asthma. Respir Med 97(5):563–567Google Scholar
  47. Harris A, Hutchinson J, Portik-Dobos V, Ergul A (2004) Decreased microvascular MMP activity in diabetes: relation to vascular remodeling and elevated endothelin-1. Cardiovasc Pathol 13:S85Google Scholar
  48. Henney AM, Ye S, Zhang B, Jormsjö S, Whatling C, Eriksson P, Hamsten A (2000) Genetic diversity in the matrix metalloproteinase family: effects on function and disease progression. Ann NY Acad Sci 902:27–37PubMedGoogle Scholar
  49. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K (2002) Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161:185–192PubMedGoogle Scholar
  50. Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF (2001) Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 156:119–125PubMedGoogle Scholar
  51. Imai K, Dalal SS, Chen ES et al (2001) Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 163:786–791PubMedGoogle Scholar
  52. Iwatsuki K, Cardinale GJ, Spector S, Udenfriend S (1977) Hypertension: increase of collagen biosynthesis in arteries but not in veins. Science 198:403–405PubMedGoogle Scholar
  53. Jacqueminet S, Abdesselam B, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL (2006) Elevated circulating levels of matrix metalloproteinase-9 in type I diabetic patients with and without retinopathy. Clin Chim Acta 367:103–107PubMedGoogle Scholar
  54. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT (1989) Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 64:1041–1050PubMedGoogle Scholar
  55. Janicki JS, Brower GL, Gardner JD, Forman MF, Stewart JA Jr, Murray DB, Chancey AL (2006) Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 69:657–665PubMedGoogle Scholar
  56. Jiang Z, Sui T, Wang B (2010) Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis. Rheumatol Int 30:1219–1226PubMedGoogle Scholar
  57. Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K (2004) Serum matrix metalloproteinase-3 in systemic sclerosis. Arch Dermatol Res 296:25–29PubMedGoogle Scholar
  58. Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59:812–823PubMedGoogle Scholar
  59. Jones JA, Zavadzkas JA, Chang EI, Sheats N et al (2010) Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg 140:653–659PubMedGoogle Scholar
  60. Jormsjö S, Ye S, Moritz J, Walter DH et al (2000) Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 86:998–1003PubMedGoogle Scholar
  61. Kaur K, Zhu K, Whittemore MS, Petersen RL, Lichte A, Tschesche H, Pourmotabbed T (2002) Identification of the active site of gelatinase B as the structural element sufficient for converting a protein to a metalloprotease. Biochemistry 41(15):4789–4797PubMedGoogle Scholar
  62. Kelly EAB, Busse WW, Jarjour NN (2000) Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 162:1157–1161PubMedGoogle Scholar
  63. Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, Cho CS (2005) Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 7:R71–R79PubMedGoogle Scholar
  64. Laviades C, Varo N, Fernandez J, Mayor G, Gil M, Monreal I, Diez J (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98:535–540PubMedGoogle Scholar
  65. Leco KJ, Apte SS, Taniguchi GT, Hawkes SP, Khokha R, Schultz GA, Edwards DR (1997) Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 401:213–217PubMedGoogle Scholar
  66. Lee SW, Song KE, Shin DS, Ahn SM et al (2005) Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 69:175–179PubMedGoogle Scholar
  67. Li YY, Feldman AM, Sun Y, McTiernan CF (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98:1728–1734PubMedGoogle Scholar
  68. Li C, Cantor WJ, Nili N et al (2002) Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor. J Am Coll Cardiol 39:1852–1858PubMedGoogle Scholar
  69. Lindsay M, Maxwel P, Dunn F (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136–141PubMedGoogle Scholar
  70. Li-Saw-He FL, Edmunds E, Blann AD, Beevers DG, Lip GYH (2000) Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol 75:43–47Google Scholar
  71. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell RRF, Thompson MM (2000) Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 31:40–47PubMedGoogle Scholar
  72. Loftus IM, Naylor AR, Bell PRF, Thompson MM (2002) Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 89:680–694PubMedGoogle Scholar
  73. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110(5):625–632PubMedGoogle Scholar
  74. Lovejoy B, Welch AR, Carr S et al (1999) Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 6:217–221PubMedGoogle Scholar
  75. Maisi P, Prikk K, Sepper R et al (2002) Soluble membrane-type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP- 2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. APMIS 110(11):771–782PubMedGoogle Scholar
  76. Mallya SK, Mookhtiar KA, Gao Y, Brew K, Dioszegi M, Birkedal-Hansen H, van Wart HE (1990) Characterization of 58-kilodalton human neutrophil collagenase: comparison with human fibroblast collagenase. Biochemistry 29:10628–10634PubMedGoogle Scholar
  77. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83:1097–1103PubMedGoogle Scholar
  78. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12:1075–1095PubMedGoogle Scholar
  79. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y (2005) Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115:599–609PubMedGoogle Scholar
  80. Maxwell PR, Timms PM, Chandran S, Gordon D (2001) Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18:777–780PubMedGoogle Scholar
  81. Molet S, Belleguic C, Lena H, Germain N et al (2005) Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res 54(1):31–36PubMedGoogle Scholar
  82. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16(5):558–564PubMedGoogle Scholar
  83. Murphy G, Hembry RM (1992) Proteinases in rheumatoid arthritis. J Rheumatol Suppl 32:61–64PubMedGoogle Scholar
  84. Murphy G, Knauper V (1997) Relating matrix metalloproteinase structure to function: why the ‘hemopexin’ domain? Matrix Biol 15(8–9):511–518PubMedGoogle Scholar
  85. Murphy G, Alian JA, Willenbrock F, Cockett ME, O’Connell JP, Docherty AJP (1992) The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem 267:9612–9618PubMedGoogle Scholar
  86. Nagase H (1996) Matrix metalloproteinases. In: Hooper NM (ed) Zinc metalloproteases in health and disease. Taylor and Francis, LondonGoogle Scholar
  87. Nagase H, Woessner JF (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494PubMedGoogle Scholar
  88. Netzel-Arnett S, Salari A, Goli UB, van Wart HE (1994) Evidence for a triple helix recognition site in the hemopexin-like domains of human fibroblast and neutrophil interstitial collagenases. Ann NY Acad Sci 732:22–30PubMedGoogle Scholar
  89. Oh J, Diaz T, Wei B, Chang H, Noda M, Stetler-Stevenson WG (2006) TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene 25(30):4230–4234PubMedGoogle Scholar
  90. Ohnishi K, Takagi M, Kurokawa Y et al (1998) Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 78(9):1077–1087PubMedGoogle Scholar
  91. Ohno I, Ohtani H, Nitta Y, Suzuki J et al (1997) Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 16:212–219PubMedGoogle Scholar
  92. Overall CM, Wiebkin OW, Thonard JC (1987) Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva. J Periodontal Res 22:81–88PubMedGoogle Scholar
  93. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DPV, Teepen H, van der Wall AC, Borst C (2000) Atherosclerotic arterial remodeling and the localization of macrophages and metalloproteases-1,2, and 9 in the human coronary artery. Atherosclerosis 150:245–253PubMedGoogle Scholar
  94. Pavlovsky AG, Williams MG, Ye Q-Z, Ortwine DF et al (1999) X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci 8:1455–1462PubMedGoogle Scholar
  95. Peschon JJ, Slack JL, Reddy P, Stocking KL et al (1998) An essential role for ectodomain shedding in mammalian development. Science 282:1281–1284PubMedGoogle Scholar
  96. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J (2004) Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 44:1609–1618PubMedGoogle Scholar
  97. Prikk K, Maisi P, Pirila E, Reintam MA, Salo T, Sorsa T, Sepper R (2002) Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest 82:1535–1545PubMedGoogle Scholar
  98. Pyo R, Lee JK, Shipley M, Curci JA et al (2000) Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105:1641–1649PubMedGoogle Scholar
  99. Romanic AM, Burns-Kurtis CL, Ao Z, Arleth AJ, Ohlstein EH (2001) Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am J Physiol Renal Physiol 281:309–317Google Scholar
  100. Sanchez-Lopez R, Alexander CM, Behrendtsen O, Breathnach R, Werb Z (1993) Role of zinc binding and hemopexin domain encoded sequences in the substrate specificity of collagenase and stromelysin-2 by chimeric proteins. J Biol Chem 268:7238–7247PubMedGoogle Scholar
  101. Sang Q-XA, Jin Y, Newcomer RG, Monroe SC, Fang X, Hurst DR, Lee S, Cao Q, Schwartz MA (2006) Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 6:289–316PubMedGoogle Scholar
  102. Schoenhagen P, Vince DG, Ziada KM, Kapadia SR et al (2002) Relation of matrix metalloproteinase-3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am J Cardiol 89:1354–1359PubMedGoogle Scholar
  103. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE (2002) Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4:439–444PubMedGoogle Scholar
  104. Segura-Valdez L, Pardo A, Gaxiola M et al (2000) Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117(3):684–694PubMedGoogle Scholar
  105. Seki M, Uzuki M, Ohmoto H, Yoshino K, Maeda S, Kokubun S, Sakurai M, Sawai T (1995) Matrix metalloproteinase (MMP-9) in patients with rheumatoid arthritis. Ryumachi 35(5):792–801PubMedGoogle Scholar
  106. Shiau M-Y, Tsai S-T, Tsai K-J, Haung M-L, Hsu Y-T, Chang Y-H (2006) Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med 73:1024–1028PubMedGoogle Scholar
  107. Silence J, Lupu F, Collen D, Lijnen HR (2001) Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 21(9):1440–1445PubMedGoogle Scholar
  108. Silence J, Collen D, Lijnen HR (2002) Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of matrixmetalloprotenase-1 (TIMP-1) gene. Circ Res 90:897–903PubMedGoogle Scholar
  109. Siwik DA, Chang DLF, Colucci WS (2000) Interleukin-1b and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86:1259–1265PubMedGoogle Scholar
  110. Somerville RPT, Oblander SA, Apte SS (2003) Matrix metalloproteinases: old dogs with new tricks. Genome Biol 4:216–220PubMedGoogle Scholar
  111. Song WW, Ergul A (2006) Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol 5:3PubMedGoogle Scholar
  112. Spinale FG, Krombach RS, Coker ML, Mukherjee R et al (1999) Matrix metalloproteinase inhibition during developing congestive heart failure in pigs, effects on left ventricular geometry and function. Circ Res 85:364–376PubMedGoogle Scholar
  113. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516PubMedGoogle Scholar
  114. Stoker W, Bode W (1995) Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr Opin Struct Biol 5:383–390Google Scholar
  115. Sundström J, Evans JC, Benjamin EJ, Levy D et al (2004) Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 25:1509–1516PubMedGoogle Scholar
  116. Sympson CJ, Talhouk RS, Bissell MJ, Werb Z (1994) The role of metalloproteinases and their inhibitors in regulating mammary epithelial morphology and function in vivo. Perspect Drug Discov Des 2:401–411Google Scholar
  117. Tamura N, Ogawa Y, Chusho H, Nakamura K et al (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97:4239–4244PubMedGoogle Scholar
  118. Tayebjee MH, Nadar S, Blann AD, Beevers DG, MacFadyen RJ, Lip GYH (2004) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17:764–769PubMedGoogle Scholar
  119. Tchetverikov I, Ronday HK, van El B et al (2004) MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 63:881–883PubMedGoogle Scholar
  120. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97:1708–1715PubMedGoogle Scholar
  121. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE et al (2007) Matrix metalloproteinase-2 dysregulation in type I diabetes. Diabetes Care 30:2321–2326PubMedGoogle Scholar
  122. Tolboom TCA, Pieterman E, van der Laan WH et al (2002) Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 61:975–980PubMedGoogle Scholar
  123. Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I (2002) The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 20:221–224PubMedGoogle Scholar
  124. Tozzi CA, Poiani GJ et al (1998) Expression of matrix-degrading enzymes in pulmonary vascular remodeling in the rat. Am J Physiol (Lung Cell Mol Physiol) 275:L398–L406Google Scholar
  125. Trysberg E, Blennow K, Zachrisson O, Tarkowski A (2004) Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 6(6):R551–R556PubMedGoogle Scholar
  126. Tsuruda T, Boerrigter G, Huntley BK, Noser JA et al (2002) Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91:1127–1134PubMedGoogle Scholar
  127. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ (1996) Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 63:185–198PubMedGoogle Scholar
  128. van Wart HE, Hansen-Birkedal H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87:5578–5582PubMedGoogle Scholar
  129. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92(8):827–839PubMedGoogle Scholar
  130. Warner RL, Bhagavathula N, Nerusu KC et al (2004) Matrix metalloproteinases in acute inflammation: induction of MMP-3 and MMP-9 in fibroblasts and epithelial cells following exposure to pro-inflammatory mediators in vitro. Exp Mol Pathol 76(3):189–195PubMedGoogle Scholar
  131. Woessner JF Jr (1994) The family of matrix metalloproteases. Ann NY Acad Sci 732:11–21PubMedGoogle Scholar
  132. Wright JL, Tai H, Wang R, Wang X, Churg A (2007) Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-α signaling. Am J Physiol Lung Cell Mol Physiol 292:L125–L133PubMedGoogle Scholar
  133. Yoshihara Y, Nakamura H, Obata K et al (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455–461PubMedGoogle Scholar
  134. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C et al (2003) Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17:119–124PubMedGoogle Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  • Viola Vargová
    • 1
    Email author
  • Marek Pytliak
    • 2
  • Viola Mechírová
    • 3
  1. 1.3rd Internal Clinic, Faculty of MedicineUPJŠKošiceSlovakia
  2. 2.Department of Nursing, Faculty of MedicineUPJŠKošiceSlovakia
  3. 3.1st Internal Clinic, Medical FacultyUPJŠKošiceSlovakia

Personalised recommendations